BIOHAVEN
"BIOHAVEN" is a word mark owned by Biohaven Therapeutics Ltd., filed at the USPTO on February 8, 2017. It is registered and covers class 5 (Pharmaceuticals).
- Status
- Registered
- Since October 14, 2026
- Filed
- February 8, 2017
- Registered
- August 18, 2020
- Expires
- Not recorded
- Application no.
- 87329452
- Registration no.
- 6130617
- Office
- USPTO
- United States Patent and Trademark Office
- Mark type
- Word mark
- 1 class
Who owns BIOHAVEN
The owner on file, matched to the company behind it. Every owner-name spelling for that company is grouped on its page.
Owner
Biohaven Therapeutics Ltd.
BHVN · Road Town, Tortola, British Virgin Islands
Representative
Monica Riva Talley
Sterne, Kessler, Goldstein & Fox P.L.L.C.
What the mark covers
The products and services BIOHAVEN is filed for, grouped by Nice class.
Medicated and pharmaceutical preparations, both prescription and over-the-counter, for use in connection with humans and animals, namely, for the treatment of central nervous system disorders, neurologic illnesses, and psychiatric illnesses; pharmaceutical preparations for the treatment of brain ischemia; pharmaceutical preparations for the treatment of brain ischemia, namely, post-stroke recovery, severe intracranial atherosclerosis, [ carotid endarterectomy, cardiac bypass, ] cerebral vasculitis, reversible cerebral vasoconstriction syndrome; pharmaceutical preparations for the treatment of brain and cord injuries; pharmaceutical preparations for the treatment of brain and cord injuries, namely, post- intracranial hemorrhage recovery, traumatic brain injury, spinal cord injury; pharmaceutical preparations for the treatment of neurodegenerative diseases; pharmaceutical preparations for the treatment of neurodegenerative diseases, namely, Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), Huntington's disease, Lewy body dementia, frontotemporal dementia, vascular dementia, Parkinson's disease, cognitive impairment of aging, progressive Multiple Sclerosis; pharmaceutical preparations for the treatment of optic and retinal neuropathies; pharmaceutical preparations for the treatment of optic and retinal neuropathies, namely, glaucoma, diabetic retinopathy, ischemic optic and retinal neuropathies; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of pain, namely, opioid sparing analgesia, cancer pain, chronic neuropathic pain, peripheral neuropathy, low back pain in the nature of failed back surgery syndrome, radiculopathy in the nature of sciatica, diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy induced neuropathy and other medication induced neuropathies, complex regional pain syndrome, fibromyalgia, chronic post-operative pain, cluster thoracotomy, phantom limb, stump neuroma; pharmaceutical preparations for the treatment of headache and facial pain, namely, headache, migraine, chronic daily headache, cluster headache, trigeminal neuralgia; pharmaceutical preparations for symptomatic treatments of degenerative diseases; pharmaceutical preparations for symptomatic treatments of degenerative diseases, namely, breath holding in Rett syndrome, dystonias, dysphagia, gait abnormalities, bulbar function in ALS, pseudobulbar affect, levodopa-induced dyskinesias in Parkinson's disease, agitation in AD, disinhibition in dementia; pharmaceutical preparations for the treatment of epilepsy; pharmaceutical preparations for the treatment of epilepsy, namely, precision medicine - adjuvant for genetic epilepsy due to NMDA receptor mutations with hyperactivation; pharmaceutical preparations for the treatment of neuropsychiatric disorders; pharmaceutical preparations for the treatment of neuropsychiatric disorders, namely, treatment resistant depression, Post Traumatic Stress Disorder (PTSD) in the nature of hyperarousal, substance abuse disorders, addiction disorders, Obsessive Compulsive Disorder (OCD), hoarding, trichotillomania, eating disorders, Generalized Anxiety Disorder (GAD), adjustment disorders, panic disorder, major depressive episode, bipolar disorder in the nature of manic and depressive episodes, dysthymia, cyclothymia, psychotic disorders, schizophrenia; pharmaceutical preparations for the treatment of cerebellar disorders; pharmaceutical preparations for the treatment of cerebellar disorders, namely, spinocerebellar ataxia, Friedriech's ataxia, multisystem atrophy, essential tremor; pharmaceutical preparations for the treatment of hearing disorders, tinnitus, delirium, sleep disorders, parasomnias, learning disorders, Attention Deficit Disorder (ADD), Pervasive Developmental Disorders (PDD), Asperger's syndrome, autism [ , menopausal hot flashes ] ; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the treatment of cancer, namely, monotherapy and adjunctive use
What has happened so far
Steps recorded by the USPTO, newest first.
- Notice of acceptance of sec. 8 & 15 - e-mailed
- Registered - sec. 8 (6-yr) accepted & sec. 15 ack.
- Case assigned to post registration paralegal
- Teas section 8 & 15 received
- Courtesy reminder - sec. 8 (6-yr) e-mailed
- Applicant/correspondence changes (non-responsive) entered
- Teas change of correspondence received
- Attorney/dom.rep.revoked and/or appointed
- Teas revoke/app/change addr of atty/dom rep received
- Teas change of owner address received
10 earlier steps on the official record.
Oppositions and cancellations
Proceedings recorded against this mark by the USPTO. Reported as recorded, not legal advice.
About BIOHAVEN
Who owns the trademark "BIOHAVEN"?
The USPTO trademark "BIOHAVEN" (application 87329452) is owned by Biohaven Therapeutics Ltd.
What is the status of "BIOHAVEN"?
Its status at the USPTO is: registered.
When was "BIOHAVEN" registered?
It was registered on August 18, 2020.
Get this data via the API
Everything on this page comes from the Signa API. Pull BIOHAVEN and marks like it into your own product with one request.
GET/v1/trademarks/{id}The full record: owners, classes, dates and images
GET/v1/trademarks/{id}/eventsEvery step in the office history
GET/v1/proceedings?trademark_id={id}Oppositions and cancellations against the mark
ID=tm_019d2b81-dcf7-7369-a2bf-88266a963629
curl https://api.signa.so/v1/trademarks/$ID \
-H "Authorization: Bearer $SIGNA_API_KEY"{
"id": "tm_019d2b81-dcf7-7369-a2bf-88266a963629",
"object": "trademark",
"mark_text": "BIOHAVEN",
"status": {
"primary": "active",
"stage": "registered"
},
"office_code": "US",
"application_number": "87329452",
"filing_date": "2017-02-08",
"nice_classes": [
5
],
"owners": [
{
"name": "BIOHAVEN THERAPEUTICS LTD.",
"entity_id": "ent_019eb7d2-fb5b-7654-8bb0-d58ab7c6ce1e"
}
]
}